http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Schall, Johannes (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Schnauber, Peter,Schall, Johannes,Bounouar, Samir,Hö,hne, Theresa,Park, Suk-In,Ryu, Geun-Hwan,Heindel, Tobias,Burger, Sven,Song, Jin-Dong,Rodt, Sven,Reitzenstein, Stephan American Chemical Society 2018 NANO LETTERS Vol.18 No.4
<P>The development of multinode quantum optical circuits has attracted great attention in recent years. In particular, interfacing quantum-light sources, gates, and detectors on a single chip is highly desirable for the realization of large networks. In this context, fabrication techniques that enable the deterministic integration of preselected quantum-light emitters into nanophotonic elements play a key role when moving forward to circuits containing multiple emitters. Here, we present the deterministic integration of an InAs quantum dot into a 50/50 multimode interference beamsplitter via in situ electron beam lithography. We demonstrate the combined emitter-gate interface functionality by measuring triggered single-photon emission on-chip with <I>g</I><SUP>(2)</SUP>(0) = 0.13 ± 0.02. Due to its high patterning resolution as well as spectral and spatial control, in situ electron beam lithography allows for integration of preselected quantum emitters into complex photonic systems. Being a scalable single-step approach, it paves the way toward multinode, fully integrated quantum photonic chips.</P> [FIG OMISSION]</BR>
-
( W. Ray Kim ),( Anu Osinusi ),( Ajitha Mannalithara ),( Bo Hyun Kim ),( Raul Aguilar Schall ),( Diana Brainard ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: Current direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection leads to sustained virological response (SVR) in the vast majority of patients, even in those with de compensated cirrhosis. SVR in patients with decompensated cirrhosis has been associated with improvement in liver func tion; however, the extent to which DAA impacts on mortality remains to be determined. We analyze mortality in patients who participated in clinical trials evaluating sofosbuvir-based regimens in patients with decompensated HCV cirrhosis (GS-US-334-0125, SOLAR and ASTRAL studies), in comparison with mortality predicted by a survival model derived in untreated HCV patients. Methods: Current direct-acting antiviral (DAA) therapy for hep atitis C virus (HCV) infection leads to sustained virological re sponse (SVR) in the vast majority of patients, even in those with decompensated cirrhosis. SVR in patients with decompensated cirrhosis has been associated with improvement in liver func tion; however, the extent to which DAA impacts on mortality remains to be determined. We analyze mortality in patients who participated in clinical trials evaluating sofosbuvir-based regimens in patients with decompensated HCV cirrhosis (GS-US-334-0125, SOLAR and ASTRAL studies), in comparison with mortality predicted by a survival model derived in untreated HCV patients. Results: There was a total of 492 patients, whose median age was 58 years, MELD 12, sodium 137mEq/l and albumin 2.9 g/ dl. Ascites and HE were common (79% and 63%, respectively). Altogether, 411/479 (86%) patients achieved SVR12. During the follow up, there were 25 deaths within one year of DAA therapy start, including 15 in the SOLAR and 10 in the ASTRAL data; no deaths occurred in GS-US-334-0125. The number of observed deaths in the clinical trials closely followed the expect ed/predicted numbers early in the treatment course (Figure). Starting at 100 days after initiation of DAA, however, the ob served number of deaths was statistically significantly smaller than expected (SMR=0.54, 95% confidence interval [CI]=0.30- 0.98). All subsequent deaths occurred at a lower frequency than expected. The last (25th) death during the study period occurred on day 339, when the SMR had decreased to 0.44 (95% CI=0.30-0.65), which remained unchanged at the end of the analysis (day 365). Conclusions: DAA therapy in patients with decompensated HCV cirrhosis leads to significantly decreased mortality, which may be apparent as early as 100 days after the initiation of therapy with the risk of mortality decreasing to 44% of the ex pected by the end of the first year.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
